UBS Securities has issued 'sell' calls on several prominent pharmaceutical companies, citing a projected slowdown in growth within the Indian and U.S. markets. The brokerage's analysis reflects concerns over declining sales opportunities in these regions, which make up a significant portion of revenues for major drugmakers. As a result, UBS has downgraded the outlook for several pharma stocks, impacting both investor sentiment and stock performance.
UBS's 'sell' calls on pharmaceutical majors
UBS has taken a cautious stance on Dr Reddy's Laboratories, Lupin, Aurobindo Pharma, and Zydus Lifesciences, recommending that investors sell shares of these companies due to potential downturns in their respective stock prices. The 'sell' recommendations are based on several factors, including high valuations, low growth prospects, and market challenges in both the U.S. and Indian markets.
For those who buy shares online, it is important to consider UBS's projected downside for these companies. Dr Reddy's has been assigned a price target of ₹5,700, representing a 15% potential decline. Zydus Lifesciences is projected to fall 19% to a target price of ₹850, while Aurobindo Pharma's price target of ₹1,333 reflects a forecasted downside of 12%. Although Lupin received a 'sell' rating,
UBS noted a minor 3% potential upside, setting a price target of ₹2,250. This projection reflects the one-off benefits expected from its respiratory drug Spiriva in FY25 and FY26, which may already be priced into the stock.
Growth challenges in the Indian and U.S. pharmaceutical markets
The Indian and U.S. markets combined account for 70-80% of total sales for most major pharmaceutical companies. UBS highlighted that these markets are facing significant growth challenges, leading to lower-than-expected financial performance for companies in the sector. For investors looking to buy shares online, this slowdown is a critical factor to consider when evaluating potential investments in pharmaceutical stocks.
UBS's preferred picks: Sun Pharma and Cipla
Despite issuing 'sell' calls on several major pharma stocks, UBS has picked Sun Pharma and Cipla as its preferred bets in the sector. The brokerage has assigned 'buy' calls for both companies, projecting a strong upside for their stocks.
Sun Pharma, one of UBS's top picks, is expected to experience a 29% upside, with a price target of ₹2,450. UBS's optimism for Sun Pharma stems from the expected revenue growth of its patented molecules, which are projected to double over the next four years. The firm also expects Sun Pharma's margin to expand by 650 basis points, leading to an earnings-per-stock (EPS) compound annual growth rate (CAGR) of 19%.
Investors interested in pharmaceutical stocks may consider buying shares online of these companies, as UBS has expressed confidence in their growth prospects.
Stock performance year to date
The share prices of Sun Pharma and Cipla have surged significantly over the past year. Sun Pharma's stock has risen by 51%, while Cipla has recorded a 29% increase in the same period. These figures reflect the confidence investors have placed in these companies' growth potential.
On the other hand, despite UBS's recent 'sell' calls, Dr Reddy's Laboratories, Lupin, Aurobindo Pharma, and Zydus Lifesciences have also shown gains ranging from 15% to 67% over the same tenure. However, UBS's bearish outlook suggests that these gains may not be sustainable in the face of the challenges ahead. Investors looking to buy shares online should take into account the potential risks and rewards associated with these stocks.
Conclusion
UBS's 'sell' calls on major pharmaceutical companies, including Dr Reddy's Laboratories, Lupin, Aurobindo Pharma, and Zydus Lifesciences, reflect the brokerage's cautious outlook on the sector. The projected slowdown in the Indian and U.S. markets, combined with regulatory pressures and heightened competition, has led UBS to recommend selling shares in these companies.
However, UBS remains optimistic about the prospects for Sun Pharma and Cipla, assigning 'buy' ratings and projecting significant upside potential for both companies. For investors planning to buy shares online, it is essential to carefully evaluate the risks and rewards associated with these stocks, particularly in light of the challenges facing the broader pharmaceutical sector.
For android only